Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
JAN$28.90-1.15(-3.83%)BUZZ-Janus Living falls on upsized $748 mln equity raise8:51:45 AM ETMU$755.50-39.96(-5.02%)How Worried Should Investors Be About Micron Right Now?8:45:37 AM ETVST$117.05-3.25(-2.70%)Vistra Cratered by 25% This Year: One Wall Street Team Says 110% Returns Ahead for Investors8:45:31 AM ETBA$177.39+0.40(+0.23%)Updating The Non-Correlateds: Boeing And IBM Trying To Become Relevant Again8:45:00 AM ETQCOM$152.76-20.43(-11.80%)Qualcomm Sinks 11% as Soft Profit Guidance and Handset Slump Overshadow Beat; Arm Holdings Drops 7%, Skyworks Slides 2%8:43:59 AM ETAMZN$271.16+5.13(+1.93%)Amazon: An Earnings Supercycle Is Taking Shape8:38:41 AM ETNVDA$197.20-3.09(-1.54%)Chinese AI lab Moonshot turned to Europe for Nvidia Blackwell access amid U.S. China curbs, sources tell CNBC8:34:14 AM ETHRL$22.98+0.22(+0.97%)3 Dividend Aristocrats Trading Below Their Historical Valuations8:34:12 AM ETTSM$384.84-10.78(-2.72%)TSMC's AI Opportunity Is Expanding. Here's the Question That Matters for Its Stock Price8:33:37 AM ETHD$359.57+4.13(+1.16%)Three Days, 36 Hands-On Workshop Sessions and HGTV's Biggest Stars: Here's What's Happening Each Day at the First-Ever DIY CON November 6-88:33:00 AM ETMCD$281.60+1.38(+0.49%)McDonald's Q3: 11% EPS Growth And A 50% Operating Margin Say The Sell-Off Was A Mistake8:30:51 AM ETTMO$711.10+4.94(+0.70%)Thermo Fisher Scientific Introduces Value-Priced Thermo Scientific™ AmpSure™ Universal qPCR Master Mixes Without Compromising Performance8:30:16 AM ETAAPL$353.50+3.99(+1.14%)Apple Stock Is Up 22%, but 1 Slowing Business Could Test That Valuation8:30:00 AM ETBRK-A$881,000.00+11,699.24(+1.35%)Two in three US-listed companies pay no dividend, a census of SEC filings finds8:30:00 AM ETTEAD$0.20-0.07(-25.93%)Ad platform Teads misses Q3 revenue estimates; suspends guidance8:29:01 AM ETC$126.42+1.65(+1.32%)UPDATE 6-Oil rises as investors weigh uncertainties around Iran war8:27:07 AM ETMCD$281.60+1.38(+0.49%)McDonald's To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Thursday8:22:06 AM ETMRNA$256.50-1.84(-0.71%)Moderna, Humana and Elanco Earnings Previews: What Investors Should Watch8:18:32 AM ETQCOM$152.76-20.43(-11.80%)Qualcomm: The AI Boom's Biggest Casualty8:18:20 AM ETAMD$460.24-28.54(-5.84%)AMD: The Bigger Earnings Opportunity Starts In 20278:17:47 AM ETV$440.30+3.71(+0.85%)Visa Just Raised Its Dividend 16%. Is It a Better Buy Than Mastercard?8:17:32 AM ETCVS$80.66+0.67(+0.84%)RPT-BREAKINGVIEWS-CVS’s problem: investors trust the warning label8:16:38 AM ETCOP$138.50+1.56(+1.14%)STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market8:15:00 AM ETMU$755.50-39.96(-5.02%)Is Micron stock a Buy after crashing below $800?8:13:57 AM ET

IRON · NASDAQ

Disc Medicine, Inc.

$83.28 +0.17 (+0.20%)

Company overview

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$3.2B
Employees
94
Headquarters
Watertown, MA
Website
discmedicine.com
CEO
John D. Quisel
Listed
August 12, 2020
P/E
-12.54
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$176,000
Operating income
-$266M
EBITDA
-$244M
Net income
-$242M
EPS
-$6.64
Total assets
$750M
Total debt
$31.1M
Earnings yield
-7.97%

Price chart

53.8061.9070.0078.1086.20
IRON 1D NASDAQ O81.50H83.57L80.78C83.11+1.95 (+2.40%)Vol525.88K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
IRONDisc Medicine, Inc. Press release Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting GlobeNewswire
IRONDisc Medicine, Inc. Press release Disc Medicine to Participate in Upcoming Investor Conferences GlobeNewswire
IRONDisc Medicine, Inc. Press release Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock GlobeNewswire
IRONDisc Medicine, Inc. Press release A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday Market Updates News Commentary - Two unrelated announcements on Monday put one of biotech's smaller corners in the spotlight. A company developing a... PR Newswire
IRONDisc Medicine, Inc. Press release Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire
IRONDisc Medicine, Inc. Stock news Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP Transcript Seeking Alpha
IRONDisc Medicine, Inc. Stock news Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study Benzinga
IRONDisc Medicine, Inc. Stock news Disc Medicine stock soars: take profit or buy into strength? Invezz
IRONDisc Medicine, Inc. Stock news Disc Medicine (IRON) Achieves Positive Phase 3 Trial Results for EPP Treatment GuruFocus
IRONDisc Medicine, Inc. Stock news Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission MarketBeat
IRONDisc Medicine, Inc. Stock news Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes Barrons
IRONDisc Medicine, Inc. Stock news Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints Proactive Investors
IRONDisc Medicine, Inc. Stock news Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday Benzinga
IRONDisc Medicine, Inc. Stock news Disc Medicine's rare disease drug succeeds in late-stage trial Reuters
IRONDisc Medicine, Inc. Press release Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP) GlobeNewswire
IRONDisc Medicine, Inc. Press release Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP) GlobeNewswire
IRONDisc Medicine, Inc. Legal ROSEN, LEADING INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Newsfile Corp
IRONDisc Medicine, Inc. Legal ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Newsfile Corp
IRONDisc Medicine, Inc. Legal ROSEN, NATIONAL TRIAL LAWYERS, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Newsfile Corp
IRONDisc Medicine, Inc. Legal ROSEN, A LEADING NATIONAL FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Newsfile Corp
See more
FAQ

Questions about Disc Medicine, Inc.

What does Disc Medicine, Inc. do?
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
What is IRON's market cap?
Disc Medicine, Inc. (IRON) is a listed stock with a live quote. The latest market cap on this page is $3.2B.
Where is Disc Medicine, Inc. headquartered?
Disc Medicine, Inc. is headquartered in Watertown, MA.
How do I get IRON news from the API?
Call GET /v1/news?tickers=IRON. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does IRON news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for IRON, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the IRON price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs